Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: A meta-analysis

Journal of Digestive Diseases

Volumn 13, Issue 4, 2012, Pages 200-207

  Tong, Jin Lu ^a   Huang, Mei Lan ^a   Xu, Xi Tao ^a   Qiao, Yu Qi ^a   Ran, Zhi Hua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Mesalamine; Meta analysis; Once daily; Ulcerative colitis

Indexed keywords

MESALAZINE;

ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MESALAMINE; RECURRENCE;

EID: 84858964894     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2012.00576.x     Document Type: Article

References (21)

1. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85.
2. Travis SP, Stange EF, Lémann M etal.; for the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008; 2: 24-62.
3. Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol 2011; 4: 237-48.
4. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 170-3.
5. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Prefer Adherence 2008; 2: 253-8.
6. Kamm MA, Lichtenstein GR, Sandborn WJ etal. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902.
7. Prantera C, Kohn A, Campieri M etal. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009; 30: 908-18.
8. Sandborn WJ, Korzenik J, Lashner B etal. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138: 1286-96, 1296.e1-3.
9. Hawthorne AB, Stenson R, Gillespie D etal. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology 2011; 140 Suppl 1: S65.
10. Kruis W, Jonaitis L, Pokrotnieks J etal; International Salofalk OD Study Group. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-22.
11. Dignass AU, Bokemeyer B, Adamek H etal. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-9.
12. Kamm MA, Sandborn WJ, Gassull M etal. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75; quiz 432-3.
13. Kruis W, Kiudelis G, Rácz I etal; International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-40.
14. Jadad AR, Moore RA, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
15. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009; 34: 41-53.
16. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33.
17. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12: 1107-13.
18. Lawlor G, Ahmed A, Moss AC. Once-daily mesalamine granules for ulcerative colitis. Expert Rev Clin Immunol 2010; 6: 521-6.
19. Lichtenstein GR, Kamm MA, Boddu P etal. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102.
20. Gandia P, Idier I, Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. J Clin Pharmacol 2007; 47: 334-42.
21. Connolly MP, Nielsen SK, Currie CJ, Poole CD, Travis SP. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis 2009; 3: 32-7.